Data demonstrated that vepdegestrant maintained patients’ quality of life for statistically significantly longer and delayed worsening of ...

Interstitial Lung Disease (ILD): In the PHAROS trial, 1 patient (1%) receiving MEKTOVI with BRAFTOVI developed pneumonitis. Assess new or progressive unexplained pulmonary symptoms or findings for ...

ITM-11 significantly improved PFS and OS compared to everolimus in GEP-NET patients, meeting primary and secondary endpoints. Subgroup analyses showed ITM-11's efficacy across tumor grades and prior ...

Pfizer is backed by strong H1 results, a promising pipeline, improved financials, and solid valuation with long-term growth potential. See why PFE stock is a buy.

NX-1607 demonstrated on-target peripheral immune activation characteristic of an active immune-oncology agent with a novel immune checkpoint ...

Results presented by AstraZeneca from its phase 3 trial of Imfinzi in patients with high-risk, non-muscle invasive bladder cancer (NMIBC) suggest the PD-L1 inhibitor measures up to Pfizer’s PD-1 ...

Pfizer Inc. experiences a mixed bag in the options market as its shares dip slightly. Currently, the stock is trading down 16 cents, positioning itself at around $24.23. With a total of 188,000 ...

Pfizer's revenue has stabilized, and a recent drug pricing deal with the US government reduces political uncertainty. Find out why PFE stock is a Strong Buy.

Pfizer's oncology portfolio has produced a second positive phase 3 trial in HER2-positive breast cancer in the span of about a year. | The positive readout could move Tukysa, which has been used for ...

J&J reports today, just two weeks after Pfizer secured certainty on tariffs and drug pricing. Analysts expect to hear about plans from the rest of the industry during third period earnings calls.

Pfizer Inc "didn't conspire with anyone" to delay release of efficacy results for the COVID-19 vaccine it developed with German partner BioNTech SE until after the U.S. presidential election, Chief ...